LYON, France, Oct. 26, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today successful completion of the first phase of the clinical protocol ...

LYON, France, January 29, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the University of Miami Sylvester Comprehensive ...

In 2015, Houston Methodist Hospital made the decision to invest in a medical technology that had not yet been approved by the US Food & Drug Administration. The procedure, called High Intensity ...

Men hoping to avoid some of the dreaded side effects of prostate cancer treatment are shelling out tens of thousands of dollars for a new procedure whose long-term effects are unknown, even though ...

LYON, France, May 9, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced a published 15-year clinical review of Ablatherm ® HIFU data supports ...

SonaCare Medical believes its treatment for prostate cancer is unusually precise and powerful, but the therapy faces a major obstacle: It is not approved in the United States. That barrier has not ...

Men hoping to avoid some side effects of prostate cancer treatment are shelling out tens of thousands of dollars for a procedure whose long-term effects are unknown and insurers, including Medicare, ...

LYON, France, March 4, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device ...

LYON, France, March 3, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announces today that the company has selected Medical Technology ...

Men hoping to avoid some side effects of prostate cancer treatment are shelling out tens of thousands of dollars for a procedure whose long-term effects are unknown and insurers, including Medicare, ...